Across TCGA pan-cancer cohorts, OR2L2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated OR2L2 data layer compared with 18 for mass-spec protein.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher OR2L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
DLBC, ESCA, and UCEC are the cancer types where OR2L2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.